| Document |
Document Title |
|
WO/2021/238908A1 |
The present invention relates to a salt and a crystal form containing a heteroaryl derivative. The present invention specifically relates to a salt and a crystal form comprising a compound of general formula (I), a preparation method, an...
|
|
WO/2021/239643A1 |
The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositi...
|
|
WO/2021/236449A1 |
Disclosed herein are p38a mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38a mitogen-activated protein kinase inhibitors.
|
|
WO/2021/236775A1 |
The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein R1, R3, L, Y, and B1 are as defined in the specification. Compounds having Formula I are SHP2 protein degraders useful for the...
|
|
WO/2021/237004A1 |
The present disclosure encompasses novel solid state forms of Aprocitentan, Aprocitentan salts and Aprocitentan co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/235283A1 |
The present invention provides: a radiation sensitive resin composition which is capable of exhibiting sensitivity, CDU performance and LWR performance at sufficient levels; and a method for forming a resist pattern. A radiation sensitiv...
|
|
WO/2021/228945A1 |
The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of fo...
|
|
WO/2021/231726A1 |
The disclosure provides compositions and methods of quinoline, quinazolines, and pyrydylpyridines derivatives for the inhibition of ENPP1 modulators.
|
|
WO/2021/226814A1 |
Disclosed are a small-molecule compound SPAM1 for up-regulating a neuropeptide PACAP and a receptor PAC1-R thereof, and a preparation method therefor and an application thereof. The structure of the SPAM1 is as shown in formula (I), wher...
|
|
WO/2021/228734A1 |
The present disclosure relates to triazine and pyrimidine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2021/224927A1 |
The invention in some embodiments thereof, relates to the field of compositions and/or pharmaceutical compositions comprising one or more biologically active compound, and is directed to methods of using same such as for treating an ApoL...
|
|
WO/2021/224802A1 |
The present invention provides a stable, liquid composition comprising: (a) a fungicidally effective amount of a compound of Formula I, and (b) a liquid carrier, wherein: (i) the composition comprises (a) a fungicidally effective and sub...
|
|
WO/2021/226629A1 |
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...
|
|
WO/2021/226260A1 |
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-py
rimidine-2,4-dione, and methods of making and using the same.
|
|
WO/2021/226258A1 |
The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-py
rimidine-2,4-dione, and methods of making and using the same.
|
|
WO/2021/225969A1 |
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disc...
|
|
WO/2021/225878A1 |
The present invention provides a compound of Formula (I): wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic per...
|
|
WO/2021/226161A1 |
An improved process for preparing verdiperstat is disclosed. The process includes the steps of reacting a compound having formula or a salt thereof, wherein R is the same or different and is each independently a C1-C5 alkyl with 3-(dimet...
|
|
WO/2021/218588A1 |
The present application belongs to the field of organic light-emitting materials, and specifically relates to a nitrogen-containing compound, an electronic component using same and an electronic device. The nitrogen-containing compound h...
|
|
WO/2021/219513A1 |
The present application relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined in the claims. The compounds of for...
|
|
WO/2021/222888A1 |
The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogen...
|
|
WO/2021/219594A1 |
The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions con...
|
|
WO/2021/218110A1 |
A benzothiazolyl biaryl compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorph, or a prodrug thereof, a prepar...
|
|
WO/2021/222365A1 |
A topical skincare composition that includes (A) a reducing sugar, (B) an aromatic sulfonate having a topological polar surface area (tPSA) of less than 100 Å2, and (C) a carrier. A method for adjusting color appearance (e.g., hue angle...
|
|
WO/2021/216705A1 |
The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compo...
|
|
WO/2021/213518A1 |
The present invention relates to the field of biomedicine, and specifically relates to an "LC3 binding portion-lipid droplet binding portion-conjugate" formed by means of covalently linking a structure capable of binding LC3 and a struct...
|
|
WO/2021/216440A1 |
The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, ...
|
|
WO/2021/212536A1 |
Disclosed is a method for preparing a gefitinib intermediate 4-(3-chloro-4-fluoroaniline)-6-acetoxy-7-methoxy quinazoline hydrochloride, comprising the following steps: step 1, putting 6-acetoxy-7-methoxy-3H quinazolin-4-one, thionyl chl...
|
|
WO/2021/216781A1 |
The present disclosure provides compounds of formula (I), (II), and (la): Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.
|
|
WO/2021/213538A1 |
Provided is a compound or a pharmaceutically acceptable salt, isomer, prodrug, polymorph, or solvate thereof, and a preparation method therefor and use thereof. The compound is used as a GnRHR antagonist in a calcium flux detection exper...
|
|
WO/2021/213111A1 |
Disclosed are a Snail inhibitor, a derivative thereof, a preparation method therefor, a pharmaceutical composition and use thereof. The Snail inhibitor has a compound structure as shown in formula (I). The Snail inhibitor derivative rela...
|
|
WO/2021/215393A1 |
Provided is the compound, or a salt thereof, represented in formula (I). (In formula (1): Ar indicates a C6-10 aryl group, etc.; R1 indicates a cyano group, a thiocarbamoyl group, etc.; R2 indicates a hydrogen atom, etc.; R 3 indicates a...
|
|
WO/2021/215537A1 |
The present invention addresses the problem of providing a 2-heteroarylaminoquinazolinone derivative. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [in the formula, X1 ...
|
|
WO/2021/211418A1 |
Provided herein are methods for treating anemia in a subject in need thereof, comprising administering to the subject an activin receptor type IIB (ActRIIB) ligand trap and administering to the subject fedratinib. Specifically, the metho...
|
|
WO/2021/209473A1 |
The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/210650A1 |
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, a...
|
|
WO/2021/209039A1 |
The present invention provides a quinazoline compound, a preparation method therefor and an application thereof, and specifically relates to a compound represented by formula (I), an isomer, a hydrate, a solvate, a pharmaceutically accep...
|
|
WO/2021/208918A1 |
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...
|
|
WO/2021/207135A1 |
The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brow...
|
|
WO/2021/204706A1 |
The present invention relates to a compound of Formula (I), wherein Q, R1 and R3, X and n are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compound...
|
|
WO/2021/198191A1 |
The present invention relates to a new class of quinazolinone derivatives of formula (I), and their uses for treating a cancer. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I).
|
|
WO/2021/203131A1 |
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
|
|
WO/2021/203048A1 |
The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), W...
|
|
WO/2021/190546A1 |
The present invention relates to the field of biotechnology, and in particular relates to a pharmaceutical composition comprising a protein kinase inhibitor and a chemotherapeutic drug and use thereof. It is found that in the treatment o...
|
|
WO/2021/195258A1 |
Provided herein is an LpxC inhibitor compound, as well as pharmaceutical compositions comprising said compound, and methods of use thereof in the treatment of disease that would benefit from treatment with an LpxC inhibitor, including gr...
|
|
WO/2021/191236A1 |
A compound according to the formula I for use in the treatment of coronavirus infection and/or a respiratory disease caused by a coronavirus, wherein R1 is chosen from alkoxy groups such as for example methoxy or ethoxy, hydroxyl group, ...
|
|
WO/2021/194326A1 |
The present invention relates to novel compounds effective as modulators Aryl hydrocarbon receptor (AhR), pharmaceutical composition comprising the compounds for the modulation of AhR, or prevention or treatment of a disease, disorder, o...
|
|
WO/2021/194261A1 |
The present invention relates to an organic light-emitting device comprising: a first electrode; a second electrode provided opposite to the first electrode; and one or more organic layers provided between the first electrode and the sec...
|
|
WO/2021/195279A2 |
Treatment of CHD1L-driven cancers, including TCF transcription-driven cancers and EMT-driven cancers using CHD1L inhibitors. Small molecule inhibitors of CHDL1 which inhibit CHD1L ATPase and inhibit CHD1L-dependent TCF-transcription have...
|
|
WO/2021/189143A1 |
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its...
|
